Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 10/20 | 0.80 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.57 |
| ▸ | PLG | P00747 | 4/20 | 0.43 |
| ▸ | PLAT | P00750 | 4/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.42 |
| ▸ | F2 | P00734 | 5/20 | 0.40 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7353483 | 0.87 | ASIC3 (0.64) | PLAUASIC3PLGPLATKLKB1 | |
| Trifluoroacetic Acid SCHEMBL7335057 | 0.86 | ASIC3 (0.79) | PLAUASIC3PLGPLATKLKB1 | |
| Trifluoroacetic Acid SCHEMBL7336009 | 0.82 | ASIC3 (0.55) | PLAUASIC3PLGPLATKLKB1 | |
| Trifluoroacetic Acid SCHEMBL7337623 | 0.81 | ASIC3 (0.53) | PLAUASIC3PLGPLATKLKB1 | |
| Trifluoroacetic Acid SCHEMBL7340242 | 0.81 | ASIC3 (0.59) | PLAUASIC3PLGPLATKLKB1 | |
| SCHEMBL7337232 | 0.79 | PLAU (1.00) | PLAUASIC3PLGPLATKLKB1 | |
| Trifluoroacetic Acid SCHEMBL7342361 | 0.78 | PLAU (0.79) | PLAUPLGPLATKLKB1PRSS1 | |
| SCHEMBL7346595 | 0.78 | PLAU (0.64) | PLAUASIC3PLGPLATKLKB1 | |
| Trifluoroacetic Acid SCHEMBL7337810 | 0.77 | ASIC3 (0.51) | PLAUASIC3PLGPLATKLKB1 | |
| Trifluoroacetic Acid SCHEMBL7344968 | 0.77 | ITGB3 (0.51) | PLAUASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885ASIC3 4314/4885PLG 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.